PURPOSE: This study aimed to assess the association between pretreatment c-Met overexpression in local-regional advanced cervical cancer patients treated definitively with concurrent chemoradiation therapy (CRT) and treatment outcomes including overall survival (OS), progression-free survival (PFS), distant metastases (DM) control, and local-regional control (LC). PATIENTS AND METHODS: This Institutional Review Board-approved study included cervical cancer patients treated definitively and consecutively with CRT. Evaluation of cytoplasmic immunoreactivity for c-Met was performed and scored semiquantitatively by 3 pathologists, blinded to the treatment outcomes, and incorporated both the intensity and percentage of immunoreactivity in invasive carcinoma (H score). Treatment outcomes were reviewed and reported. Outcomes were stratified by c-Met overexpression and tumor characteristics. OS, PFS, LC, and DC rates were obtained via the Kaplan-Meier method and differences between groups were evaluated by the log-rank test. Hazard ratios were obtained via Cox regression for both univariate and multivariate analyses. RESULTS: The 5-year OS, PFS, LC, and DC were 57.18%, 48.07%, 72.11%, and 62.85%, respectively. Ten (35.7%) and 18 patients (64.3%) had c-Met H index >30 and<30, respectively. c-Met overexpression was significantly associated with worse 3- and 5-year OS (P=0.003), PFS (P=0.002), LC (P=0.01), and DC (P=0.0003). Patients with c-Met overexpression had a hazard ratio of 6.297, 5.782, 6.28, and 18.173 for the risks of death, disease progression, local recurrence, and DM, respectively. CONCLUSION: c-Met overexpression could be a potential predictive marker and therapeutic target for local-regional advanced cervical cancer patients treated definitively with CRT.
PURPOSE: This study aimed to assess the association between pretreatment c-Met overexpression in local-regional advanced cervical cancerpatients treated definitively with concurrent chemoradiation therapy (CRT) and treatment outcomes including overall survival (OS), progression-free survival (PFS), distant metastases (DM) control, and local-regional control (LC). PATIENTS AND METHODS: This Institutional Review Board-approved study included cervical cancerpatients treated definitively and consecutively with CRT. Evaluation of cytoplasmic immunoreactivity for c-Met was performed and scored semiquantitatively by 3 pathologists, blinded to the treatment outcomes, and incorporated both the intensity and percentage of immunoreactivity in invasive carcinoma (H score). Treatment outcomes were reviewed and reported. Outcomes were stratified by c-Met overexpression and tumor characteristics. OS, PFS, LC, and DC rates were obtained via the Kaplan-Meier method and differences between groups were evaluated by the log-rank test. Hazard ratios were obtained via Cox regression for both univariate and multivariate analyses. RESULTS: The 5-year OS, PFS, LC, and DC were 57.18%, 48.07%, 72.11%, and 62.85%, respectively. Ten (35.7%) and 18 patients (64.3%) had c-Met H index >30 and<30, respectively. c-Met overexpression was significantly associated with worse 3- and 5-year OS (P=0.003), PFS (P=0.002), LC (P=0.01), and DC (P=0.0003). Patients with c-Met overexpression had a hazard ratio of 6.297, 5.782, 6.28, and 18.173 for the risks of death, disease progression, local recurrence, and DM, respectively. CONCLUSION:c-Met overexpression could be a potential predictive marker and therapeutic target for local-regional advanced cervical cancerpatients treated definitively with CRT.
Authors: Benjamin E Greer; Wui-Jin Koh; Nadeem R Abu-Rustum; Sachin M Apte; Susana M Campos; John Chan; Kathleen R Cho; Larry Copeland; Marta Ann Crispens; Nefertiti Dupont; Patricia J Eifel; David K Gaffney; Warner K Huh; Daniel S Kapp; John R Lurain; Lainie Martin; Mark A Morgan; Robert J Morgan; David Mutch; Steven W Remmenga; R Kevin Reynolds; William Small; Nelson Teng; Fidel A Valea Journal: J Natl Compr Canc Netw Date: 2010-12 Impact factor: 11.908
Authors: Eric D Donnelly; Tamer Refaat; Michelle Gentile; Alex Herskovic; John Boyle; Irene Helenowski; Alfred Rademaker; John Lurain; Julian Schink; Diljeet Singh; Jonathan B Strauss; William Small Journal: Am J Clin Oncol Date: 2015-10 Impact factor: 2.339
Authors: Chao-Nan Qian; Xiang Guo; Brian Cao; Eric J Kort; Chong-Chou Lee; Jindong Chen; Ling-Mei Wang; Wei-Yuan Mai; Hua-Qing Min; Ming-Huang Hong; George F Vande Woude; James H Resau; Bin Tean Teh Journal: Cancer Res Date: 2002-01-15 Impact factor: 12.701
Authors: R Pearcey; M Brundage; P Drouin; J Jeffrey; D Johnston; H Lukka; G MacLean; L Souhami; G Stuart; D Tu Journal: J Clin Oncol Date: 2002-02-15 Impact factor: 44.544
Authors: Tracey Schefter; Kathryn Winter; Janice S Kwon; Kelly Stuhr; Khalid Balaraj; Brian Patrick Yaremko; William Small; William Sause; David Gaffney Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-01 Impact factor: 7.038
Authors: Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Bradley J Monk; Michael W Sill; Robert A Burger; Heidi J Gray; Thomas E Buekers; Lynda D Roman Journal: J Clin Oncol Date: 2009-01-12 Impact factor: 44.544
Authors: Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544